natgillin/translations-raw huggingface dataset:
In subgroup analyses the point estimate of the HR was 0.495 for subjects 13 to 14 years of age compared to 0.454 for subjects 15 to 17 years of age. 
Pri analizi podskupin je bila ocenjena vrednost RO pri preskušancih, starih od 13 do 14 let, 0,495 v primerjavi s preskušanci, starimi od 15 do 17 let, pri katerih je razmerje bilo 0,454.
If you have the impression that the effect of Aripiprazole Zentiva is too strong or too weak, talk to your doctor or pharmacist. 
Če menite, da je učinek zdravila Aripiprazol Zentiva premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. 
Bolniki z redko dedno intoleranco za galaktozo, popolnoma zmanjšano aktivnostjo laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Treatment should be initiated at 2 mg (using an appropriate aripiprazole containing medicinal product) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. 
Zdravljenje je treba uvesti v odmerku 2 mg (z uporabo primernega zdravila, ki vsebuje aripiprazol), ki ga bolnik jemlje 2 dni, nato pa se odmerek poveča do odmerka 5 mg, ki ga bolnik jemlje še dodatna 2 dni.
After a 13 - 26 week stabilisation on aripiprazole (2 - 15 mg/day) patients with a stable response were either maintained on aripiprazole or substituted to placebo for further 16 weeks. 
Po 13-26 tednih stabilizacije na aripiprazolu (2-15 mg/dan) so bolniki s stabilnim odzivom nadaljnjih 16 tednov bodisi ostali na aripiprazolu ali pa so prešli na placebo.
If you take more Aripiprazole Zentiva than you should If you realise you have taken more Aripiprazole Zentiva than your doctor has recommended (or if someone else has taken some of your Aripiprazole Zentiva), contact your doctor right away. 
Če ste vzeli večji odmerek zdravila Aripiprazol Zentiva, kot bi smeli Če ugotovite, da ste vzeli več zdravila Aripiprazol Zentiva, kot vam je priporočil zdravnik (ali če je vaše zdravilo Aripiprazol Zentiva vzel kdo drug), se takoj posvetujte s svojim zdravnikom.
Irritability associated with autistic disorder 
Razdražljivost, povezana z avtistično motnjo
In contrast the 95% confidence interval for the HR in the older subgroup (aripiprazole, n = 69; placebo, n = 36) was 0.242 to 0.879 and hence a treatment effect could be concluded in the older patients. 
V nasprotju s tem je bil 95-% interval zapanja za RO pri starejši podskupini (aripiprazol, n = 69; placebo, n = 36) od 0,242 do 0,879, tako da je pri starejših bolnikih mogoče sprejeti zaključek o učinkovitosti zdravljenja.
These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or preoccupation with an increase in sexual thoughts or feelings. 
To se imenuje motnja nadzora impulzov, kamor štejemo vedenja, kot so odvisnost od hazardiranja, čezmerno uživanje hrane ali trošenje denarja, nenormalno povečan libido ali preokupacija z mislimi na spolnost ali spolnimi občutki.
Therefore, Aripiprazole Zentiva is not recommended for use in patients below 13 years of age (see sections 4.8 and 5.1). 
Uporabe zdravila Aripiprazol Zentiva se zato pri bolnikih, mlajših od 13 let, ne priporoča (glejte poglavji 4.8 in 5.1).
However, the concentrations of the sulphate conjugates of hydroxy aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6% of the bile concentrations found in the monkeys in the 39-week study and are well below (6%) their limits of in vitro solubility. 
Vendar je bila koncentracija sulfatnih konjugatov hidroksiaripiprazola v človeškem žolču v 39-tedenski raziskavi ob največjem priporočenem odmerku 30 mg na dan le 6 % koncentracije v žolču pri opicah ter je bila bistveno pod mejo (6 %) njihove topnosti in vitro.
In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56 - 99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer's disease, patients treated with aripiprazole were at increased risk of death compared to placebo. 
V treh s placebom nadzorovanih preskušanjih (n = 938, povprečna starost: 82,4 leta, razpon: 5699 let) aripiprazola pri starejših bolnikih s psihozo, povezano z Alzheimerjevo boleznijo, je bilo tveganje smrti večje pri bolnikih, ki so dobivali aripiprazol, kot pri tistih, ki so dobivali placebo.
The following side effects have been reported since the marketing of oral aripiprazole but the frequency for them to occur is not known: 
O naslednjih neželenih učinkih so poročali v obdobju od prihoda zdravila aripiprazol v peroralni obliki na trg; pogostnost pojavljanja le-teh pa ni znana:
• Triptans (such as sumatriptan and zolmitripitan) used for treating migraine 
• triptane (kot sta sumatriptan in zolmitriptan) uporabljamo za zdravljenje migrene.
The safety profile in a 26-week open-label extension trial was similar to that observed in the shortterm, placebo-controlled trial. 
V 26-tedenskem, odprtem, podaljšanem preskušanju je bil profil varnosti podoben profilu varnosti v kratkotrajnem, s placebom nadzorovanem preskušanju.
Actual scores in rating scales used as secondary endpoints, including PANSS and the Montgomery-Asberg Depression Rating Scale showed a significant improvement over haloperidol. 
Dejanske ocene po ocenjevalnih lestvicah (vključno s PANSS in lestvico Montgomery-Asberg Depression Rating Scale), ki so predstavljale sekundarne končne točke, so pokazale značilno izboljšanje v primerjavi s haloperidolom.
Potential for aripiprazole to affect other medicinal products In clinical studies, 10 - 30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan). 
V kliničnih študijah odmerki od 10 do 30 mg aripiprazola na dan niso pomembno vplivali na presnovo substratov CYP2D6 (razmerje dekstrometorfan/3-metoksimorfinan), CYP2C9 (varfarin), CYP2C19 (omeprazol) ali CYP3A4 (dekstrometorfan).
Aripiprazole Zentiva is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. 
Zdravilo Aripiprazol Zentiva je indicirano za zdravljenje shizofrenije pri odraslih in mladostnikih, starih 15 let in več.
It is important that you carry on taking Aripiprazole Zentiva for as long as your doctor has told you to. 
Pomembno je, da zdravljenje z zdravilom Aripiprazol Zentiva nadaljujete tako dolgo, kot vam je svetoval zdravnik.
The safety and efficacy of aripiprazole in children and adolescents aged below 18 years have not yet been established. 
Varnost in učinkovitost aripiprazola pri otrocih in mladostnikih, mlajših od 18 let, še nista bili dokazani.
In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107%, while Cmax was unchanged. 
V kliničnem preskušanju pri zdravih preiskovancih je močan zaviralec CYP2D6 (kinidin) zvečal AUC aripiprazola za 107 %, Cmax pa se ni spremenila.
• Muscle stiffness, and drowsiness or sleepiness, slower breathing, choking, high or low blood pressure, abnormal rhythms of the heart. 
• okorelost mišic in omotičnost ali zaspanost, upočasnjeno dihanje, dušenje, visok ali nizek krvni tlak, motnje srčnega ritma.
Tics associated with Tourette's disorder 
Trzaji, povezani s Tourettovim sindromom
The rate of death in aripiprazoletreated patients was 3.5% compared to 1.7% in the placebo group. 
Delež smrti je bil v skupini z aripiprazolom 3,5 % in v skupini s placebom 1,7 %.
Extrapyramidal symptoms were mainly reported during the stabilisation phase in 17% of patients, with tremor accounting for 6.5%. 
O ekstrapiramidnih simptomih so poročali predvsem med stabilizacijsko fazo, in sicer pri 17 % bolnikov, od tega je 6,5 %
• in blood tests: increased or fluctuating blood sugar, increased glycosylated haemoglobin. 
• krvne preiskave: povišanje ali nihanje ravni sladkorja v krvi, zvišana raven glikoziliranega hemoglobina,
What you need to know before you take Aripiprazole Zentiva Do not take Aripiprazole Zentiva 
Kaj morate vedeti, preden boste vzeli zdravilo Aripiprazol Zentiva Ne jemljite zdravila Aripiprazol Zentiva
Class effect - Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. 
Učinek zdravil iz te skupine (“Class Effect”) - V prvih nekaj dneh zdravljenja se lahko pri dovzetnih posameznikih pojavijo simptomi distonije, podaljšane nenormalne kontrakcije mišičnih skupin.
In a 60- to 89-week, randomised, double-blind, placebo-controlled trial in adolescent subjects (n = 146; ages 13 - 17 years) with schizophrenia, there was a statistically significant difference in the rate of relapse of psychotic symptoms between the aripiprazole (19.39%) and placebo (37.50%) groups. 
V 60- do 89-tedenskem, randomiziranem, dvojnoslepem, s placebom kontroliranem preskušanju pri mladostnikih s shizofrenijo (n = 146; v starosti od 13 do 17 let) je bilo opaziti statistično značilno razliko v stopnji ponovitve psihotičnih simptomov med skupinama bolnikov, zdravljenih z aripiprazolom (19,39 %) in s placebom (37,50 %).
What Aripiprazole Zentiva is and what it is used for 
Kaj je zdravilo Aripiprazol Zentiva in za kaj ga uporabljamo
Orodispersible tablets may be used as an alternative to Aripiprazole Zentiva tablets for patients who have difficulty swallowing Aripiprazole Zentiva tablets (see section 5.2). 
Orodisperzibilne tablete se lahko uporabijo kot alternativa tabletam Aripiprazol Zentiva pri bolnikih, ki tablete Aripiprazol Zentiva težko pogoltnejo (glejte poglavje 5.2).
The Kaplan-Meier rates for recurrence to any mood episode for the adjunctive treatment arm were 16% in aripiprazole + lithium and 18% in aripiprazole + valproate compared to 45% in placebo + lithium and 19% in placebo + valproate. 
Po Kaplan-Meierjevi metodi izračunani deleži ponovitev katerekoli razpoloženjske epizode pri uporabi dodatnega zdravila so bili 16 % pri uporabi kombinacije aripiprazol + litij in 18 % pri uporabi kombinacije aripiprazol + valproat v primerjavi s 45 % pri kombinaciji placebo + litij ter 19 % pri kombinaciji placebo + valproat.
• Acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating, 
• akutno zmedenost, krče (epilepsijo), komo, kombinacijo zvišane telesne temperature, hitrega dihanja, znojenja;
Aripiprazole Zentiva is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1). 
Zdravilo Aripiprazol Zentiva je indicirano za zdravljenje zmernih do hudih maničnih epizod pri bipolarni motnji I ter za preprečevanje novih maničnih epizod pri odraslih bolnikih, ki so doživljali pretežno manične epizode, ki so bile odzivne na zdravljenje z aripiprazolom (glejte poglavje 5.1).
The most common treatment-emergent adverse events among patients receiving 30 mg were extrapyramidal disorder (28.3%), somnolence (27.3%), headache (23.2%), and nausea (14.1%). 
Pri bolnikih, ki so prejemali odmerek 30 mg, so bili najpogostejši neželeni učinki ektrapiramidne motnje (28,3 %), zaspanost (27,3 %), glavobol (23,2 %) in navzea (14,1 %).
Aripiprazole Zentiva is used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling “high”, having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability. 
Zdravilo Aripiprazol Zentiva uporabljamo za zdravljenje odraslih in mladostnikov, starih 13 let in več, ki imajo težave s simptomi, kot so evforično razpoloženje, pretirana energija, zmanjšana potreba po spanju, hitro govorjenje s prehitevajočimi mislimi in občasno huda razdražljivost.
Aripiprazole showed an improvement on TTS-YGTSS change from baseline to week 8 of 13.35 for the low dose group (5 mg or 10 mg) and 16.94 for the high dose group (10 mg or 20 mg) as compared with an improvement of 7.09 in the placebo group. 
Po jemanju aripiprazola je bilo 8. teden vidno izboljšanje s spremembo od izhodiščne vrednosti rezultata TTS-YGTSS za 13,35 točk pri skupini z nizkim odmerkom (5 ali 10 mg) in za 16,94 točk pri skupini z visokim odmerkom (10 ali 20 mg) v primerjavi z izboljšanjem za 7,09 točk pri skupini, ki je prejemala placebo.
Population pharmacokinetic evaluation has revealed no evidence of clinically significant effects from smoking on the pharmacokinetics of aripiprazole. 
Populacijska farmakokinetična analiza ni pokazala klinično pomembnih učinkov kajenja na farmakokinetiko aripiprazola.
Patients were 6 - 18 years and presented an average score of 29 on TTS-YGTSS at baseline. 
Bolniki so bili stari od 6 do 18 let, njihov povprečni izhodiščni rezultat na lestvici TTS-YGTSS pa je bil 29.
In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (see section 5.1). 
V kliničnih preskušanjih in v obdobju trženja aripiprazola so za odobrene indikacije opazili povečanje in zmanjšanje serumskega prolaktina v primerjavi z izhodiščnimi vrednostmi (poglavje 5.1).
Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the geometric means of Cmax and AUC for aripiprazole were 68% and 73% lower, respectively, compared to when aripiprazole (30 mg) was administered alone. 
Po sočasni uporabi karbamazepina, močnega induktorja CYP3A4, in peroralnega aripiprazola pri bolnikih s shizofrenijo in shizoafektivno motnjo je bila geometrična sredina Cmax za 68 % nižja, AUC pa za 73 % nižja kot po uporabi samega aripiprazola (30 mg).
The safety and efficacy of aripiprazole in children and adolescents 6 to 18 years of age have not yet been established. 
Varnost in učinkovitost aripiprazola pri otrocih in mladostnikih, starih od 6 do 18 let, še ni bili dokazani.
Aripiprazole has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8). 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Aripiprazol ima blag do zmeren vpliv na sposobnost vožnje in upravljanje strojev zaradi morebitnega vpliva na živčni sistem in vid, kot je sedacija, somnolenca, sinkopa, zamegljen vid in diplopija (glejte poglavje 4.8).
Elevations of CPK (Creatine Phosphokinase), generally transient and asymptomatic, were observed in 3.5% of aripiprazole treated patients as compared to 2.0% of patients who received placebo. 
Zvišanje CPK (kreatin-fosfokinaze), ki je praviloma prehodno in asimptomatsko, je bilo zabeleženo pri 3,5 % bolnikov, zdravljenih z aripiprazolom, in pri 2,0 % bolnikov, ki so dobivali placebo.
Venous thromboembolism (including pulmonary embolism and deep vein thrombosis) 
Žilne bolezni ortostatska hipotenzija venska trombembolija (vključno s pljučno embolijo in globoko vensko trombozo) hipertenzija sinkopa
What you need to know before you take Aripiprazole Zentiva 
Kaj morate vedeti, preden boste vzeli zdravilo Aripiprazol Zentiva
In a 26-week, placebo-controlled trial in adult stabilised patients with chronic schizophrenia, aripiprazole had significantly greater reduction in relapse rate, 34% in aripiprazole group and 57% in placebo. 
V 26-tedenskem, s placebom nadzorovanem preskušanju stabiliziranih odraslih bolnikov s kronično shizofrenijo je aripiprazol značilno bolj zmanjšal delež recidivov: v skupini, ki je dobivala aripiprazol, jih je bilo 34 %, v tisti, ki je dobivala placebo, pa 57 %.
In a clinical trial in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by 63% and 37%, respectively. 
V kliničnem preskušanju pri zdravih preiskovancih je močan zaviralec CYP3A4 (ketokonazol) zvečal AUC aripiprazola za 63 % in Cmax za 37 %.
• feeling tired. 
• bruhanje, • utrujenost.
Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated although individual patients may benefit from a higher dose. 
Pri odmerkih, višjih od 10 mg/dan, večje učinkovitosti niso dokazali, vendar pa posameznim bolnikom lahko koristi tudi zdravljenje z večjim odmerkom.
• Medicines to correct heart rhythm (such as quinidine, amiodarone, flecainide) 
• zdravila proti motnjam srčnega ritma (kot so kinidin, amiodaron, flekainid),
The recommended starting dose for Aripiprazole Zentiva is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1). 
Priporočeni začetni odmerek zdravila Aripiprazol Zentiva je 15 mg enkrat na dan ne glede na obroke hrane, in sicer kot samostojno zdravilo ali v sklopu kombiniranega zdravljenja (glejte poglavje 5.1).
The following adverse reactions had a possible dose response relationship; extrapyramidal disorder (incidences were 10 mg, 9.1%, 30 mg, 28.8%, placebo, 1.7%,); and akathisia (incidences were 10 mg, 12.1%, 30 mg, 20.3%, placebo, 1.7%). 
Naslednji neželeni učinki bi lahko bili povezani z velikostjo odmerka: ekstrapiramidne motnje (pri uporabi 10 mg odmerka je bila pojavnost 9,1 %, pri uporabi 30 mg odmerka 28,8 %, pri uporabi placeba pa 1,7 %) in akatizija (pri uporabi 10 mg odmerka je bila pojavnost 12,1 %, pri uporabi 30 mg odmerka 20,3 %, pri uporabi placeba pa 1,7 %).
• Antifungal medicines (such as ketoconazole, itraconazole) 
• zdravila proti glivicam (kot sta ketokonazol, itrakonazol),
The recommended starting dose for Aripiprazole Zentiva is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals. 
Priporočeni začetni odmerek zdravila Aripiprazol Zentiva je 10 ali 15 mg/dan, vzdrževalni odmerek pa 15 mg/dan, uporabljen enkrat na dan ne glede na obroke.
If you are taking Aripiprazole Zentiva, your doctor will discuss with you whether you should breast feed considering the benefit to you of your therapy and the benefit to your baby of breast feeding. 
Če prejemate zdravilo Aripiprazol Zentiva, vam bo zdravnik pomagal pri odločitvi glede dojenja z upoštevanjem prednosti dojenja za otroka in prednosti zdravljenja za vas.
The following symptoms may occur in newborn babies, of mothers that have used Aripiprazole Zentiva in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. 
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo Aripiprazol Zentiva, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
• Certain medicines to treat HIV infection (such as efavirenz, nevirapine, an protease inhibitors e.g. indinavir, ritonavir) 
• določena zdravila za zdravljenje okužbe s HIV (kot so efavirenz, nevirapin, zaviralci proteaz,
In adults it also prevents this condition from returning in patients who have responded to the treatment with Aripiprazole Zentiva. 
Zdravilo tudi preprečuje ponovitve pri odraslih bolnikih, ki so se odzvali na zdravljenje z zdravilom Aripiprazol
Each tablet contains 5 mg/10 mg/15 mg/30 mg of aripiprazole. 
Ena tableta vsebuje 5 mg/10 mg/15 mg/30 mg aripiprazola.
Irritability associated with autistic disorder in paediatric patients (see section 4.2) Aripiprazole was studied in patients aged 6 to 17 years in two 8-week, placebo-controlled trials [one flexible-dose (2 - 15 mg/day) and one fixed-dose (5, 10, or 15 mg/day)] and in one 52-week openlabel trial. 
Razdražljivost, povezana z avtistično motnjo, pri pediatričnih bolnikih (glejte poglavje 4.2) Uporabo aripiprazola so pri bolnikih, starih od 6 do 17 let, raziskovali v dveh 8-tedenskih, s placebom nadzorovanih preskušanjih [v enem z uporabo fleksibilnega odmerka (od 2 do 15 mg/dan), v drugem pa z uporabo fiksnega odmerka (5, 10 ali 15 mg/dan)] in v enem 52-tedenskem odprtem preskušanju.
Potential for other medicinal products to affect aripiprazole A gastric acid blocker, the H2 antagonist famotidine, reduces aripiprazole rate of absorption but this effect is deemed not clinically relevant. 
Zaviralec izločanja želodčne kisline, antagonist H2 famotidin, zmanjša hitrost absorpcije aripiprazola, vendar ta učinek ne velja za klinično pomembnega.
Aripiprazole Zentiva tablets contain lactose. 
Tablete Aripiprazol Zentiva vsebujejo laktozo.
The safety profile of a long-term, double-blind placebo controlled trial was also similar except for the following reactions that were reported more frequently than paediatric patients taking placebo: weight decreased, blood insulin increased, arrhythmia, and leukopenia were reported commonly 
Profil varnosti v dolgotrajnem dvojnoslepem, s placebom nadzorovanem kliničnem preskušanju je bil prav tako podoben, razen pri naslednjih reakcijah, o katerih so poročali pogosteje pri pediatričnih bolnikih, ki so jemali placebo: pogosto so navajali zmanjšanje telesne mase, zvišano vrednost inzulina v krvi, aritmijo in levkopenijo (≥ 1/100, < 1/10).
• Anticonvulsants used to treat epilepsy (such as carbamazepine, phenytoin, phenobarbital) 
• antikonvulzive, ki se uporabljajo za zdravljenje epilepsije (kot so karbamazepin, fenitoin,
- If you have any further questions, ask your doctor or pharmacist. 
− Če imate dodatna vprašanja, se posvetujte z zdravnikom ali s farmacevtom.
• Other anti-depressants (such as venlafaxine and tryptophan) used in major depression 
• druge antidepresive (kot sta venlafaksin in triptofan) uporabljamo za veliko depresijo,
Similarly, for dehydro-aripiprazole the geometric means of Cmax and AUC after carbamazepine co-administration were 69% and 71% lower, respectively, than those following treatment with aripiprazole alone. 
Podobno je bila po sočasni uporabi karbamazepina geometrična sredina Cmax dehidroaripiprazola za 69 % nižja, njegova AUC pa za 71 % nižja kot po zdravljenju s samim aripiprazolom.
Aripiprazole Zentiva is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1). 
Zaradi nezadostnih podatkov o varnosti in učinkovitosti uporaba zdravila Aripiprazol Zentiva pri bolnikih s shizofrenijo, mlajših od 15 let, ni priporočljiva (glejte poglavji 4.8 in 5.1).
• slower heart beat, 
• počasnejše bitje srca,
In a 6-week placebo-controlled trial involving 302 schizophrenic adolescent patients (13 - 17 years), presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo. 
V 6-tedenskem s placebom nadzorovanem preskušanju, ki je vključevalo 302 mladostnika (13-17 let) s shizofrenijo s pozitivnimi in negativnimi simptomi, je bil aripiprazol povezan s statistično značilno večjim izboljšanjem psihotičnih simptomov v primerjavi s placebom.
Recurrence prevention of manic episodes in Bipolar I Disorder For preventing recurrence of manic episodes in patients who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose. 
Preprečevanje ponovitev maničnih epizod pri bipolarni motnji I Za preprečevanje ponovitev maničnih epizod pri bolnikih, ki so se zdravili z aripiprazolom samostojno ali v sklopu kombiniranega zdravljenja, se zdravljenje nadaljuje z istim odmerkom.
Pathological gambling and other impulse control disorders Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. 
Pri bolnikih se lahko poveča impulzivnost, zlasti želja po igrah na srečo, med jemanjem aripiprazola pa teh niso več sposobni nadzorovati.
• Antidepressants or herbal remedy used to treat depression and anxiety (such as fluoxetine, 
• antidepresive ali pripravke rastlinskega izvora proti depresiji in tesnobnosti (kot so fluoksetin,